Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. This milestone strengthens the company’s position in the biotech sector, which operates alongside its mining division focused on rare earth and precious metals projects in Greenland.
The Canadian patent issuance is significant because it provides additional protection for a technology that could address major unmet medical needs in neurodegenerative diseases. According to the World Health Organization, dementia affects over 55 million people globally, with Alzheimer’s disease contributing to 60-70% of cases. Parkinson’s disease impacts more than 10 million people worldwide, and ALS has a lifetime risk of approximately 1 in 300. The Klotho gene has been associated with longevity and cognitive function, making it a promising target for therapies aimed at slowing or reversing neurodegeneration.
Greenland Mines’ biotech division focuses on developing Klotho-based gene therapies, with KLTO-202 as the primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure. The patent news underscores the company’s commitment to diversifying its portfolio beyond mining into high-potential biotechnology assets.
For more details, the full press release is available at https://ibn.fm/x2pHA. Updates on GRML can be found in the company’s newsroom at https://ibn.fm/GRML.
